Deep vein thrombosis after hip fracture surgery: a prospective, randomized trial of the use of low-dose aspirin

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400094173

Enrollment

Unknown

Registered

2024-12-18

Start date

2025-01-01

Completion date

Unknown

Last updated

2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip pain, swelling, shortening of the lower limb, and limited hip movement.

Interventions

A group (Nadroparin calcium):None

B group (Nadroparin calcium + aspirin 100 mg):None

C group (Natlanheparin calcium + aspirin 200mg):None

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Hip fractures admitted to the hospital within 24 hours after injury. (2) Over 18 years old. (3) Undergoing surgical treatment for hip fractures. (4) Signing the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Hospital stay is less than 48 hours. (2) Pathological fractures, open fractures. (3) Patients undergoing continuous anticoagulant therapy. (4) Severe liver and kidney diseases. (5) Patients with abnormal blood coagulation function diseases before fracture or with contraindications to the use of anticoagulant drugs. (6) Patients with mental disorders and other expected poor compliance.

Design outcomes

Primary

Measure	Time frame
Deep vein thrombosis (DVT);	—

Countries

China

Contacts

Public ContactZHANG XIAO HUI

shangraodongxindiwuyiyuan

zhangxiaohuijy@sina.com+86 793 8156302

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026